

## Community Counts: Exploring Transcription Regulation & Immunotherapy for ES-SCLC

### Clinical Case #1

#### References

Agency for Healthcare Research and Quality. Five Major Steps to Intervention (The "5 A's"). Updated December 2012. Accessed October 13, 2021.

<https://www.ahrq.gov/prevention/guidelines/tobacco/5steps.html>

Baize N, Monnet I, Greillier L, et al. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. *The Lancet Oncology*. 2020;21(9):1224-1233. doi:10.1016/s1470-2045(20)30461-7

Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. *J Thorac Oncol*. 2020;15(4):618-627. doi:10.1016/j.jtho.2019.12.109

HYCAMTIN® (topotecan) [prescribing information]. Novartis Pharmaceuticals Corporation. Approved 1996. Revised October 2019.

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/020671s024lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020671s024lbl.pdf)

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer (v1.2022). Updated August 9, 2021. Accessed September 29, 2021.

[https://www.nccn.org/professionals/physician\\_gls/pdf/sclc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf)

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Smoking Cessation (v1.2021). Updated February 18, 2021. Accessed October 13, 2021.

[https://www.nccn.org/professionals/physician\\_gls/pdf/smoking.pdf](https://www.nccn.org/professionals/physician_gls/pdf/smoking.pdf)

Pietanza MC, Kadota K, Huberman K, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. *Clin Cancer Res*. 2012;18(4):1138-45. doi:10.1158/1078-0432.CCR-11-2059

Ready N, Farago AF, de Braud F, et al. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. *J Thorac Oncol*. 2019;14(2):237-244. doi:10.1016/j.jtho.2018.10.003

Subbiah V, Paz-Ares L, Besse B, et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. *Lung Cancer*. 2020;150:90-96. doi:10.1016/j.lungcan.2020.10.003

Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. *The Lancet Oncology*. 2020;21(5):645-654. doi:10.1016/s1470-2045(20)30068-1

ZEPZELCA™ (lurbinectedin) [prescribing information]. Jazz Pharmaceuticals, Inc. Approved 2020. Revised June 2020. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/213702s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf)

## Glossary

2L, second-line therapy  
AE, adverse event  
ALT, alanine aminotransferase  
AST, aspartate transaminase  
Carbo, carboplatin  
CAV, cyclophosphamide/doxorubicin/vincristine  
CI, confidence interval  
CNS, central nervous system  
CR, complete response  
CT, computed tomography  
CTFI, chemotherapy-free interval  
Cyclophos, cyclophosphamide  
DCR, disease control rate  
DOR, duration of response  
Doxo, doxorubicin  
ES-SCLC, extensive-stage small-cell lung cancer  
Etop, etoposide  
HR, hazard ratio  
IO, immunotherapy  
IV, intravenous  
mDOR, median duration of response  
Mets, metastases  
mOS, median overall survival  
mPFS, median progression-free survival  
MRI, magnetic resonance imaging  
NA, not applicable  
NCCN, National Comprehensive Cancer Network  
Nivo, nivolumab  
NR, not reported  
NRT, nicotine replacement therapy  
OS, overall survival  
ORR, overall response rate  
Pembro, pembrolizumab  
PD-L1, programmed death-ligand 1  
PFS, progression-free survival  
PO, by mouth  
PR, partial response  
SCLC, small-cell lung cancer  
Taxol, paclitaxel  
TMZ, temozolomide  
Vinc, vincristine